Cardiovascular · Investigational
Ularitide (Urodilatin)
No lawful US pathway
01 · Overview
Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in kidney tubular cells. Like other natriuretic peptides it acts on guanylyl cyclase A receptors to raise cyclic GMP, promoting vasodilation and sodium excretion.
It was developed as an intravenous vasodilator for acute decompensated heart failure, with the aim of reducing cardiac wall stress and improving long-term prognosis (PMID 28402745).
02 · Research summary & key findings
In the TRUE-AHF trial (New England Journal of Medicine, 2017), 2,157 patients with acute heart failure received ularitide or placebo for 48 hours; cardiovascular death did not differ between groups and the hierarchical clinical composite endpoint was not improved (PMID 28402745). Ularitide did lower systolic blood pressure and NT-proBNP levels but did not change troponin T, suggesting physiological effects without reduced myocardial injury (PMID 28402745). Regulatory approval was not obtained.
03 · Regulatory status
Ularitide (Urodilatin) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Ularitide (Urodilatin) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 4 FDA-approved compounds in Cardiovascular
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Intravenous
References
- [1]Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure N Engl J Med, 2017. PMID 28402745
Primary literature
- PubMed: "Ularitide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Ularitide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Ularitide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cardiovascular
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.